Lysophosphatidic acid species are associated with exacerbation in chronic obstructive pulmonary disease.

ABSTRACT:

Background

Chronic obstructive pulmonary disease (COPD) exacerbations are heterogenous and profoundly impact the disease trajectory. Bioactive lipid lysophosphatidic acid (LPA) has been implicated in airway inflammation but the significance of LPA in COPD exacerbation is not known. The aim of the study was to investigate the utility of serum LPA species (LPA16:0, 18:0, 18:1, 18:2, 20:4) as biomarkers of COPD exacerbation.

Patients and methods

LPA species were measured in the baseline placebo sera of a COPD randomized controlled trial. Tertile levels of each LPA were used to assign patients into biomarker high, medium, and low subgroups. Exacerbation rate and risk were compared among the LPA subgroups.

Results

The levels of LPA species were intercorrelated (rho 0.29-0.

SUBMITTER: Li Q 

PROVIDER: S-EPMC8461999 | biostudies-literature | 2021 Sep

REPOSITORIES: biostudies-literature